Wyeth works with Solvay

zoom

Wyeth Pharmaceuticals and Solvay Pharmaceutical have entered into a new neuroscience discovery, co-development, and co-commercialisation agreement. As announced in April 2004, Wyeth and Solvay previously entered into co-development and co-commercialisation agreements for bifeprunox and other neuroscience compounds. This collaboration has already resulted in a New Drug Application submitted on October 11, 2006 to the US Food and Drug Administration for bifeprunox for the treatment of patients with schizophrenia.

Development continues on two other clinical stage neuroscience projects, SLV-313 and SLV-314, which were part of the 2004 deal.

Under the new agreements, the parties will collaborate in a joint discovery effort targeting the identification of small molecules as potential anti-psychotic medications.

Any compounds discovered as part of the research collaboration will be jointly co-owned and patented by Wyeth and Solvay as well as co-developed and co-commercialised by the two companies. “Pooling the experiences and know-how of Solvay and Wyeth will enhance the probability for the discovery of a number of novel pre-development neuroscience candidates,” said Menelas Pangalos, Ph.D., vice president, neuroscience discovery, Wyeth Research.

Print | Email | Discuss this article |

USER COMMENTS (0 COMMENTS)

POST A COMMENT

CLICK HERE TO POST A COMMENT

Add your Comment All posts are sent to the administrator for review and are published only after approval. ArabianBusiness.com reserves the right to remove any comment at any time for any reason. Please keep your responses appropriate and on topic.
Name *
Remember me on this computer
Email *	(Your email address will not be published)
City
Country
Subject *
Comment *
Notify me of further comments
Security Code *
Please click post only once - your comment will not be published immediately.